ArticleCancers2022

Role of Brachytherapy Boost in Clinically Localized Intermediate and High-Risk Prostate Cancer: Lack of Benefit in Patients with Very High-Risk Factors T3b-4 and/or Gleason 9-10.

Hideya Yamazaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.